Medicare Enrolled
Dr. Scott Stone, MD
Medical Oncology · Plano, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Stone from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Stone? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Stone
Dr. Scott Stone is a medical oncology in Plano, TX, with 19 years in practice. Based on federal Medicare data, Dr. Stone performed 72,697 Medicare services across 3,731 unique beneficiaries.
Between the years covered by Open Payments, Dr. Stone received a total of $17,457 from 53 pharmaceutical and/or device companies across 208 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Stone is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 14% volume in TX$ $17,457 industry payments
Medicare Practice Summary
Medicare Utilization ↗72,697
Medicare services
Top 14% in TX for medical oncology
3,731
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,826 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 24,200 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 14,505 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 8,400 | $44 | $138 |
| Contrast dye for imaging (iodine-based) | 7,116 | $0 | $3 |
| Paclitaxel chemotherapy injection | 3,274 | $0 | $8 |
| Immune globulin infusion (Octagam) | 3,140 | $33 | $234 |
| Dexamethasone injection (steroid) | 1,352 | $0 | $1 |
| Blood draw (venipuncture) | 1,147 | $8 | $20 |
| Comprehensive metabolic blood panel | 1,096 | $10 | $64 |
| Complete blood count (CBC) with differential | 1,063 | $8 | $36 |
| Denosumab injection (Prolia/Xgeva) | 1,020 | $18 | $66 |
| Office visit, established patient (20-29 min) | 887 | $62 | $250 |
| Injection, granisetron hydrochloride, 100 mcg | 800 | $0 | $24 |
| Injection of additional new drug or substance into vein | 392 | $11 | $108 |
| Ferritin level test (iron stores) | 349 | $13 | $60 |
| Iron level test | 343 | $6 | $27 |
| Iron binding capacity test | 343 | $9 | $35 |
| Anti-nausea injection (Aloxi/palonosetron) | 330 | $1 | $114 |
| Lactate dehydrogenase (enzyme) level | 288 | $6 | $31 |
| Administration of chemotherapy into vein, 1 hour or less | 244 | $96 | $707 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 190 | $48 | $313 |
| Reticulated (young) platelet measurement | 122 | $35 | $143 |
| Drug injection, under skin or into muscle | 120 | $11 | $96 |
| Office visit, established patient (30-39 min) | 115 | $89 | $368 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 110 | $20 | $128 |
| Carcinoembryonic antigen (cea) protein level | 107 | $19 | $99 |
| Injection, carboplatin, 50 mg | 107 | $2 | $300 |
| Injection, diphenhydramine hcl, up to 50 mg | 96 | $1 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 78 | $48 | $344 |
| Injection, zoledronic acid, 1 mg | 78 | $7 | $431 |
| Ct scan of chest with contrast | 76 | $51 | $821 |
| Unclassified drugs | 71 | $1 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 70 | $22 | $157 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 70 | $90 | $657 |
| Microscopic examination for white blood cells with manual cell count | 69 | $4 | $22 |
| Complete blood count (CBC), automated | 69 | $6 | $34 |
| Administration of chemotherapy into vein, each additional hour | 67 | $21 | $161 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 66 | $1,110 | $4,802 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 63 | $15 | $100 |
| Infusion, normal saline solution , 1000 cc | 63 | $2 | $19 |
| CT scan of abdomen and pelvis with contrast | 61 | $169 | $1,067 |
| PSA test (prostate cancer screening) | 61 | $18 | $94 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 60 | $55 | $211 |
| Hospital follow-up visit, moderate complexity | 50 | $61 | $247 |
| New patient office visit (30-44 min) | 43 | $80 | $372 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 37 | $23 | $145 |
| Infusion into a vein for hydration, each additional hour | 35 | $10 | $75 |
| Red blood count automated, with additional calculations | 30 | $5 | $26 |
| CT scan of chest, without contrast | 28 | $35 | $686 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 27 | $15 | $94 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev | 26 | $177 | $700 |
| Drawing of blood for a medical problem | 24 | $56 | $264 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 24 | $367 | $1,722 |
| Ct scan of abdomen and pelvis without contrast | 22 | $79 | $560 |
| New patient office visit (45-59 min) | 22 | $127 | $565 |
| Hospital follow-up visit, low complexity | 22 | $38 | $135 |
| Administration of additional new drug or substance into vein using push technique | 16 | $42 | $289 |
| Injection of drug or substance into vein | 13 | $28 | $247 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.9% high complexity
86.0% medium
9.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$17,457
Total received (2018-2024)
Avg $2,494/year across 7 years
Top 32% in TX for medical oncology
53
Companies
208
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$9,148 (52.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,212 (24.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,098 (23.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,650
2023$1,522
2022$1,064
2021$1,144
2020$2,750
2019$134
2018$9,192
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Teva Pharmaceuticals USA, Inc.
$9,697
Deciphera Pharmaceuticals Inc.
$1,200
Novocure Inc.
$1,048
AstraZeneca Pharmaceuticals LP
$541
Alexion Pharmaceuticals, Inc.
$456
Novartis Pharmaceuticals Corporation
$366
Merck Sharp & Dohme LLC
$357
Athenex Pharmaceutical Division, LLC
$350
PFIZER INC.
$286
Novocure GmbH
$250
COMSORT, Inc
$250
Daiichi Sankyo Inc.
$194
Gilead Sciences, Inc.
$183
Blueprint Medicines Corporation
$173
Seattle Genetics, Inc.
$172
Kite Pharma, Inc.
$152
GENZYME CORPORATION
$117
ABBVIE INC.
$108
EMD Serono, Inc.
$98
E.R. Squibb & Sons, L.L.C.
$98
Regeneron Healthcare Solutions, Inc.
$91
Janssen Biotech, Inc.
$91
BeiGene USA, Inc.
$87
Pharmacyclics LLC, An AbbVie Company
$80
Celgene Corporation
$76
SOBI, INC
$73
CTI BioPharma Corp.
$69
JAZZ PHARMACEUTICALS INC.
$67
Bayer Healthcare Pharmaceuticals Inc.
$64
Incyte Corporation
$52
Takeda Pharmaceuticals U.S.A., Inc.
$46
Seagen Inc.
$43
RECORDATI_RARE_DISEASES_INC.
$41
SERVIER PHARMACEUTICALS LLC
$39
Genentech USA, Inc.
$39
Amgen Inc.
$38
Tempus AI, Inc
$28
AVEO Pharmaceuticals, Inc.
$26
Stemline Therapeutics Inc.
$26
Mirati Therapeutics, Inc.
$25
AbbVie Inc.
$25
Acrotech Biopharma LLC
$24
Legend Biotech USA Inc.
$23
Rigel Pharmaceuticals, Inc.
$22
GE HealthCare
$21
Iovance Biotherapeutics, Inc.
$20
Medtronic USA, Inc.
$20
Eisai Inc.
$19
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
GlaxoSmithKline, LLC.
$18
Kyowa Kirin, Inc.
$17
Exelixis Inc.
$16
Blue Earth Diagnostics Limited
$15
Top 3 companies account for 68.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AYVAKIT · Amtagvi · Axumin · BAVENCIO · BELEODAQ · BENDEKA · BOSULIF · BRUKINSA · CABLIVI · Cabometyx · DARZALEX · Doptelet · ELREXFIO · ENHERTU · EPKINLY · ERLEADA · Enhertu · FOTIVDA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LOCAMETZ · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · OPDIVO · OSTEOCOOL RF ABLATION · OXBRYTA · Oncology · Orserdu · PIQRAY · PLUVICTO · Phesgo · Pomalyst · Poteligeo · QINLOCK · RYBREVANT · Rezlidhia · SARCLISA · SCEMBLIX · SYLVANT · Soliris · Stivarga · TABRECTA · TEPMETKO · TEVIMBRA · TREANDA · TUKYSA · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · VONJO · Vonjo · XTANDI · Yescarta · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (52%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Equivalent to $24 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
75
Per 100K population
6.7
County median income
$117,588
Nearest hospital
MEDICAL CITY PLANO
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Stone is a mixed practice specialist, with above-average Medicare volume (top 14% in TX), and speaking/promotional industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Stone experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Stone performed 24,200 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Stone receive payments from pharmaceutical companies?
Yes. Dr. Stone received a total of $17,457 from 53 companies across 208 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Stone's costs compare to other medical oncologys in Plano?
Dr. Stone's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Stone) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Plano
Browse medical oncologys in Plano ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Teva Pharmaceuticals USA, Inc. Payments to Doctors
See all physicians who received payments from Teva Pharmaceuticals USA, Inc..
By company
Deciphera Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Deciphera Pharmaceuticals Inc..
By company
Novocure Inc. Payments to Doctors
See all physicians who received payments from Novocure Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology